Connect with us

Health

Nigerian drugmaker Fidson selected to manufacture generic influenza antiviral under global licence

info

Published

on

Untitled design 17.png

A Nigerian pharmaceutical company, Fidson Healthcare Plc, has been selected to develop and manufacture a generic version of baloxavir marboxil, an antiviral medicine used to treat influenza.

The selection makes Fidson one of 11 manufacturers across nine countries chosen under a voluntary licensing agreement between the Medicines Patent Pool (MPP) and Swiss pharmaceutical company Roche.

The company disclosed this in a press release signed by its media contact, Tope Akindele. The MPP, a United Nations-backed public health organisation, also announced the sublicence agreements on 25 September.

The selected manufacturers are from Brazil, China, India, Indonesia, Malaysia, Nigeria, Uganda, Ukraine and Vietnam. The MPP said the arrangement is intended to “diversify supply pathways for influenza treatment, support regional production, and strengthen preparedness for future outbreaks and pandemics.”

What it means for Fidson, Nigeria

The selection makes Fidson one of the manufacturers that would develop, manufacture and supply generic versions of baloxavir in 129 countries covered by the licence, subject to regulatory authorisation.

The agreement also gives selected manufacturers access to technical data, reference products for bioequivalence studies and other support to facilitate product development and regulatory approval.

PT WHATSAPP CHANNEL
Dangote Refinery AD

The MPP said it selected the manufacturers following an open Expression of Interest process and an assessment of their technical and regulatory capacities and commitment to producing quality-assured baloxavir products.

The organisation said having manufacturers in different regions would help build production capacity closer to the populations the medicines are intended to serve and strengthen the resilience of global supply.

For Nigeria, the selection places a local pharmaceutical manufacturer in a global effort to expand production of an influenza antiviral while strengthening domestic and regional pharmaceutical manufacturing capacity.

Selection strengthens Africa’s role

Fidson’s Managing Director and Chief Executive Officer, Biola Adebayo, described the selection as a validation of the company’s commitment to quality-assured pharmaceutical manufacturing and innovation.

“Being selected by the Medicines Patent Pool as a sublicensee under the Roche-MPP voluntary licensing programme for baloxavir marboxil is both an honour and a validation of Fidson’s longstanding commitment to quality-assured pharmaceutical manufacturing, innovation, and improving healthcare outcomes,” Mr Adebayo said.

He said the partnership would allow the company to contribute to efforts to strengthen regional health security and preparedness for future health emergencies.

“As an African healthcare company, we are proud to contribute to global efforts aimed at strengthening regional health security, enhancing preparedness for future health emergencies, and ensuring that life-saving medicines reach the patients who need them most,” he said.

Mr Adebayo said the partnership also demonstrated the growing role of African manufacturers in the global health ecosystem.

He said Fidson would work with Roche, the MPP and other stakeholders to support broader access to baloxavir across eligible markets.

READ ALSO: Fidson, Nigeria’s largest pharmaceutical company, delivers N3.6 billion dividend to shareholders

Part of pandemic preparedness

The announcement came as global leaders gathered in New York for the United Nations General Assembly to discuss pandemic prevention, preparedness and response.

The MPP said the licensing arrangement is designed to build manufacturing capacity before, rather than during, a health emergency.

Charles Gore, Executive Director of the MPP, said the organisation would work with the selected manufacturers on product development and regulatory approval, aiming to make quality-assured generic baloxavir available as quickly as possible.

“By combining global manufacturing capacity with regionally focused production, we are helping build a more geographically diverse and resilient supply base for the future,” Mr Gore said.


Discover more from Premium Times Nigeria

Subscribe to get the latest posts sent to your email.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Health

Diphtheria: MSF warns of treatment shortages as Nigeria records over 1,100 deaths

info

Published

on

MSF389856High scaled.jpg

Médecins Sans Frontières (MSF) has warned that shortages of a lifesaving medicine are forcing medical teams to ration treatment for diphtheria patients in northern Nigeria, where more than 28,000 confirmed infections and 1,100 deaths have been reported this year.

The warning comes as figures attributed to the Nigeria Centre for Disease Control and Prevention (NCDC) show that the outbreak continues to spread, particularly among children who are unvaccinated or have not received all their recommended vaccine doses.

In a statement issued on Friday, MSF said supplies of diphtheria antitoxin (DAT), which neutralises the toxin responsible for potentially fatal complications, were dangerously low.

The organisation called on federal and state authorities, donors and international partners to urgently secure additional medicines and vaccines, ensure their timely clearance at ports and improve distribution to affected communities.

Treatment shortage threatens patients

MSF’s Medical Coordinator in Nigeria, David Kizito, warned that the shortage could compromise the treatment of severely ill patients.

“Our stocks are dangerously low, and we risk being unable to treat children and save lives as the outbreak continues,” he said.

PT WHATSAPP CHANNEL
Dangote Refinery AD
MSF photograph of a healthcare worker examining a diphtheria patient at the Infectious Disease Hospital in Amanawa, Sokoto, on 8 October 2026
MSF photograph of a healthcare worker examining a diphtheria patient at the Infectious Disease Hospital in Amanawa, Sokoto, on 8 October 2026

Diphtheria is a vaccine-preventable bacterial infection that can cause fever, sore throat and a thick membrane in the throat, sometimes obstructing breathing. Severe infections can damage the heart, nerves and kidneys.

According to the World Health Organisation (WHO), diphtheria antitoxin neutralises toxins circulating in the bloodstream, while antibiotics help eliminate the bacteria and reduce transmission.

Early administration of antitoxin is particularly important because it cannot reverse damage once the toxin has entered body cells.

MSF said limited global production and inconsistent availability had left treatment facilities struggling to obtain adequate supplies.

However, the organisation did not specify which facilities had exhausted their stocks, how many patients had been unable to obtain treatment or whether any deaths were directly attributable to the shortages.

Nigeria records 1,126 deaths

The warning comes amid a prolonged outbreak that began in late 2022.

PREMIUM TIMES reports that a situation report issued on 11 November by the International Federation of Red Cross and Red Crescent Societies (IFRC) and the Nigerian Red Cross Society, citing NCDC data, indicates that Nigeria recorded 37,529 suspected diphtheria cases, 28,151 confirmed infections and 1,126 deaths in 2026 as of 7 November.

The report said the outbreak had affected 26 states and the Federal Capital Territory, covering 361 local government areas.

Kano accounted for 12,008 confirmed cases, approximately 43 per cent of the national total.

The figures are substantially higher than those in MSF’s latest statement, which relied on NCDC statistics from 9 August, when 406 deaths had been reported for 2026.

The difference reflects reporting from separate periods and may include subsequent updates to surveillance records.

Katsina: 70 severe cases in 18 days

In Katsina State, MSF reported managing 86 diphtheria cases between 26 October and 12 November, including 70 classified as severe and 16 as non-severe.

Severe infections accounted for approximately 81 per cent of the patients managed by its teams during the period, although the figures do not represent the severity of all diphtheria infections recorded across the state.

MSF said its teams also reached 1,315 contacts through surveillance and contact-tracing activities. Of these, 1,301 received vaccinations, while 1,311 were given preventive antibiotics.

The organisation did not provide the locations of the cases or a breakdown of recoveries and deaths.

The development follows earlier concerns about the capacity of health facilities to manage the outbreak.

On 31 August, PREMIUM TIMES reported that the Federal Teaching Hospital (FTH), Katsina, was struggling with an influx of suspected and confirmed diphtheria patients, leaving its children’s ward under considerable pressure.

The hospital attributed the overcrowding partly to referrals from other facilities across the state.

In response, the federal government announced an emergency multi-agency task force to strengthen surveillance, immunisation and access to treatment in Katsina and Kano.

The intervention included plans to supply additional antitoxin, antibiotics, medical personnel and protective equipment to FTH Katsina.

Authorities also announced plans to establish treatment annexes across Katsina’s three senatorial districts — Katsina, Daura and Funtua — to reduce pressure on the referral hospital.

MSF’s latest statement did not indicate whether those facilities had become operational or how much additional antitoxin had been delivered since the intervention was announced.

Zamfara vaccine shortage

In neighbouring Zamfara State, MSF said its supported facilities in Gusau recorded more than 671 diphtheria admissions over approximately one month beginning on 6 October.

Most patients were children, while four out of every five had not been vaccinated.

The organisation also reported a substantial shortfall in vaccine supplies for an emergency immunisation campaign.

Of the 90,000 doses required, only 25,000 had been supplied, representing approximately 28 per cent of the stated requirement.

MSF said it was working with government health authorities to secure the outstanding doses and expand vaccination activities.

The shortfall highlights the continuing difficulties facing efforts to protect children against the disease.

In October, PREMIUM TIMES reported that the Executive Director of the National Primary Health Care Development Agency (NPHCDA), Muyi Aina, said about 93 per cent of children affected by recent diphtheria outbreaks had not received their full recommended vaccine doses.

Mr Aina said some had never been vaccinated, while others had received fewer than the three recommended doses. He identified misinformation and vaccine hesitancy among the challenges affecting immunisation uptake.

MSF’s response

Despite the challenges, MSF said its teams had treated more than 9,000 diphtheria patients through facility-based and community interventions since the beginning of its 2026 response.

In Kano, the organisation supported vaccination campaigns in April and June, administering more than 835,000 doses to children in partnership with the state Ministry of Health.

READ ALSO: Meningitis: Anambra, Ebonyi, Enugu intensify vaccination, urge residents to stay hydrated

It also supported two vaccination rounds in Sokoto between February and April, reaching 49,018 children under 15.

The organisation said it was supporting treatment, surveillance, infection prevention and vaccination efforts in several northern states, alongside government health authorities.

MSF called for increased global production of diphtheria antitoxin and sustained investment in routine childhood immunisation to prevent further outbreaks.

The latest warning also draws renewed attention to the emergency measures announced by the federal government in August, particularly the delivery of antitoxin supplies and the proposed expansion of treatment facilities in Katsina.

The extent to which those interventions have improved access to treatment remains to be established.


Discover more from Premium Times Nigeria

Subscribe to get the latest posts sent to your email.

Continue Reading

Health

North accounts for most of Nigeria’s recorded maternal deaths – Report

info

Published

on

40 1602x1068 1.jpg

Women in northern Nigeria continue to bear a disproportionate burden of maternal deaths, with the Northwest and Northeast geopolitical zones accounting for about three-quarters of reported fatalities in health facilities, according to the 2026 Joint Annual Review (JAR) Statistical Book.

The report also highlights significant disparities in maternal health outcomes between rural and urban areas, with rural women recording a maternal mortality ratio of 656 deaths per 100,000 live births, compared with 444 deaths per 100,000 live births in urban areas.

Produced by the Federal Ministry of Health and Social Welfare, the report reviews the third year of implementation of the Health Sector Strategic Blueprint. It was presented at the third Nigeria Health Sector Joint Annual Review in Abuja on 10 November.

The findings highlight persistent inequalities in maternal healthcare access and outcomes, despite a reported decline in maternal deaths across health facilities nationally.

According to the report, Nigeria recorded thousands of maternal deaths in health facilities between January and September 2026, although the figures represent only deaths captured by the facility reporting system.

The ministry acknowledged that the figures could be underreported or overreported but described the data as reliable for monitoring trends in the health sector.

PT WHATSAPP CHANNEL
Dangote Refinery AD

Maternal mortality remains high

Maternal mortality refers to the death of a woman during pregnancy, childbirth or within 42 days of the termination of pregnancy from causes related to or aggravated by the pregnancy or its management.

Most maternal deaths are preventable through timely access to quality antenatal care, skilled birth attendance, emergency obstetric services and appropriate postnatal care.

Despite the reported improvements, Nigeria’s maternal mortality ratio remains a major public health concern.

The JAR Statistical Book puts the country’s maternal mortality ratio at 572 deaths per 100,000 live births, significantly above the Sustainable Development Goal (SDG) target of fewer than 70 deaths per 100,000 live births by 2030.

The burden is particularly concerning given Nigeria’s contribution to global maternal deaths.

In its 2023 report, titled “Improving Maternal and Newborn Health and Survival and Reducing Stillbirths: Progress Report 2023”, the World Health Organisation (WHO) estimated that Nigeria recorded 82,000 maternal deaths, 181,000 stillbirths and 277,000 neonatal deaths in 2020.

The combined 540,000 deaths accounted for 12 per cent of global maternal, stillbirth and neonatal deaths, despite Nigeria contributing only six per cent of global live births.

The report ranked Nigeria second after India among countries with the highest combined burden of maternal deaths, stillbirths and neonatal deaths.

Reported maternal deaths decline

The JAR data indicate a downward trend in facility-reported maternal deaths over the review period.

The country recorded 5,391 maternal deaths in health facilities in 2024, compared with 4,455 in 2025.

The figure declined further in 2026, although the exact total requires confirmation against the final statistical table. The quarterly data also indicate improvements.

Following a peak in the second quarter of 2024, maternal deaths and the maternal mortality ratio generally declined. By the third quarter of 2026, the maternal mortality ratio had fallen to 128 deaths per 100,000 live births, representing a reduction of about 46 per cent from the earlier peak.

Maternal deaths during the same period also declined by approximately 40 per cent to 947.

However, these improvements have not been evenly distributed across the country.

Northern states bear the burden

According to the report, maternal deaths over the past three years were heavily concentrated in the Northwest and Northeast geopolitical zones.

By 2026, the two zones together accounted for approximately three-quarters of all documented maternal deaths in health facilities.

The five northern states with the highest maternal mortality burden were Kano, Borno, Jigawa, Yobe and Katsina.

While the national figures showed a downward trend, maternal deaths reportedly increased across the two northern zones, contrasting with reductions recorded in southern parts of the country.

ALSO READ: Faith leaders urged to confront beliefs, family decisions driving maternal deaths in Kano

In most southern states, fewer than 50 maternal deaths were reported. The states with the lowest recorded numbers included Osun (four deaths), Abia (five), Enugu (eight), Ekiti (nine), and Bayelsa (nine).

Maternal morbidity

Beyond deaths, the report also highlights the burden of maternal morbidity, including complications that can have lasting effects on women’s health, wellbeing and livelihoods. In 2026, approximately 3,060 women were diagnosed with vesicovaginal fistula (VVF), compared with 4,350 in 2025.

VVF is an abnormal opening between the bladder and vagina that can result in continuous, involuntary leakage of urine, often following prolonged or obstructed labour.

Of the women diagnosed in 2026, 1,737 underwent surgical repair, representing 56.8 per cent of those diagnosed. This was lower than in 2025, when 2,564 women (59 per cent) underwent repairs.

The Northwest and Northeast again recorded the highest burden, with 1,420 and 982 cases, respectively, in 2026. The figures underscore the need to strengthen access to emergency obstetric care, timely referrals and surgical treatment, particularly in underserved communities.


Discover more from Premium Times Nigeria

Subscribe to get the latest posts sent to your email.

Continue Reading

Trending